The AstraZeneca PLC ADR AZN slumped 0.66% to $78.38 Friday, on what proved to be an all-around mixed trading session for the ...

The Food and Drug Administration announced Friday it had broadened the approval of the FluMist nasal spray to become the ...

The FDA is clearing the way for an at-home flu vaccines. A self-administered version of pharmaceutical giant AstraZeneca’s ...

The Food and Drug Administration (FDA) announced Friday it has approved the first flu vaccine that can be self-administered, ...

The Food and Drug Administration on Friday approved the first at-home flu vaccine, a nasal spray that consumers with a ...

In a first, the US Food and Drug Administration on Friday approved a nasal spray flu vaccine for self-administration.

The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's influenza nasal spray vaccine for ...

The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's nasal spray flu vaccine for ...

The latest trading day saw Astrazeneca (AZN) settling at $78.38, representing a -0.66% change from its previous close.

FluMist is a nasal spray manufactured by AstraZeneca that has been used to protect against influenza in the United States ...

Key Insights ...

AstraZeneca has announced that FluMist has been approved in the US as the self-administered influenza vaccine. FluMist, a ...